New CEOs Need Digit...
Health Care: Drugs
Amicus Therapeutics Inc. (FOLD: NASDAQ)
$2.46 -0.06 | -2.19%
06/19/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 2.46 |
| 52 Week High | 6.89 |
| 52 Week Low | 2.30 |
| Avg. Daily Vol. (Mil) | 0.42 |
| Beta (3 year) | 1.93 |
| Share Related Items | |
| Mkt Cap (Mil) | 122.09 |
| Shares Out (Mil) | 49.63 |
| Float (Mil) | 25.21 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 10.00 |
| Current Ratio | 11.00 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.01 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 11.48 |
| Price/Book | 2.29 |
| Price/Cash Flow | -1.90 |
| Per Share Data | |
| Earnings | -1.08 |
| Sales | 0.21 |
| Book Value | 1.07 |
| Cash Flow | -1.30 |
| Business Summary | |
|---|---|
| Amicus Therapeutics, Inc. is a biopharmaceutical company in the development stage. Its activities include raising capital, establishing facilities, and performing research and development. | |
| General Information | |
| 1 Cedar Brook Drive
Cranbury, NJ 08512 |
|
| www.amicusrx.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 112 | |
| CEO: John F. Crowley | |
| Short Interest | |
| Current Month (Mil) | 4.59 |
| Previous Month (Mil) | 4.42 |
| Short Interest Ratio (Days) | 15.30 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -71.10 |
| Return on Investments | -123.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with FOLD
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserWatchlist
- ContributorStocks With Big Insider Buy...
- Contributor22 Biopharma Stocks With Br...
Latest FOLD Headlines from TheStreet
- Stocks Gain Despite Late Speculation on Fed Tapering 06.17.13 | 04:06 pm
- Amicus Delays U.S. Approval Filing for Fabry Disease Drug 06.17.13 | 08:06 am
- Amicus Therapeutics To Host Conference Call Today At 8:00 A.m. ET To Discuss Regulatory Strategy For Migalastat HCl Monotherapy For Fabry Disease 06.17.13 | 06:06 am
- Biotech Stock Mailbag: 2013 Clinical Trials Calendar 06.07.13 | 07:06 am
- Commit To Buy Amicus Therapeutics At $2.50, Earn 25.9% Annualized 05.31.13 | 01:05 pm
- Amicus Therapeutics To Present At Jefferies 2013 Global Healthcare Conference 05.30.13 | 10:05 am
- Amicus Therapeutics To Present At UBS Global Healthcare Conference 05.14.13 | 10:05 am
- Amicus Therapeutics Announces First Quarter 2013 Financial Results And Corporate Updates 05.09.13 | 04:05 pm
- Amicus Therapeutics To Announce First Quarter 2013 Financial Results On May 9, 2013 05.02.13 | 12:05 pm
- Amicus Therapeutics To Present At 12th Annual Needham Healthcare Conference 04.24.13 | 10:04 am
Press Releases for FOLD
- Amicus Therapeutics Joins Russell 3000® Index - PR Newswire 06.27.11 | 09:06 am
- Amicus Therapeutics To Present At Jefferies 2011 Global Healthcare Conference On Tuesday, June 7, 2011 - PR Newswire 05.31.11 | 09:05 am
- Amicus Therapeutics Announces Transition Of John F. Crowley From Chairman And Chief Executive Officer To Executive Chairman - PR Newswire 04.18.11 | 04:04 pm
- Amicus Therapeutics To Present At The 13th Annual BIO CEO And Investor Conference On Tuesday, February 15, 2011 - PR Newswire 02.10.11 | 08:02 am
- Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal⢠Co-administered With Enzyme Replacement Therapy - PR Newswire 02.09.11 | 07:02 am
- Amicus Therapeutics To Host Its Third Quarter 2010 Financial Results Conference Call And Webcast On November 8, 2010 - PR Newswire 11.02.10 | 08:11 am
- Amicus Therapeutics To Host Conference Call And Webcast To Discuss Exclusive Worldwide Agreement With GSK To Develop And Commercialize Amigal⢠For Fabry Disease - PR Newswire 10.29.10 | 06:10 am
- Amicus Therapeutics To Present At The BIO Investor Forum On October 5, 2010 - PR Newswire 09.30.10 | 08:09 am
- Amicus Therapeutics To Present At The Canaccord Genuity 30th Annual Growth Conference On August 12, 2010 - PR Newswire 08.04.10 | 08:08 am
- Amicus Therapeutics To Host Its Second Quarter 2010 Financial Results Conference Call And Webcast On August 5, 2010 - PR Newswire 07.27.10 | 08:07 am
Partner Headlines for FOLD
- Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed - Seeking Alpha 05.14.13 | 10:05 am
- Curing Parkinson's: The Alternative Approach - Is There Money To Be Made? - Seeking Alpha 04.04.13 | 09:04 am
- After-Hours Earnings Report for March 12, 2013 : KW, DOLE, ACAD, GCA, GNMK, AVID, WSR, KTOS, GERN, ACRX, FOLD, GCAP - NASDAQ 03.12.13 | 06:03 pm
- Mid-Week Biopharma Catalyst Trades To Consider - Seeking Alpha 12.13.12 | 09:12 am
- Glaxo Invests in Nigeria - Analyst Blog - Zacks 11.28.12 | 09:11 am
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- 3 Best Biotech Stocks For This Week (Part V) - Seeking Alpha 10.08.12 | 09:10 am
- Glaxo Aims to Expand Synflorix Label - Analyst Blog - NASDAQ 09.19.12 | 03:09 pm
- Glaxo Increases Stake in RGDX - Analyst Blog - NASDAQ 09.18.12 | 09:09 pm
- Glaxo to Increase Stake in Amicus - Analyst Blog - Zacks 07.19.12 | 06:07 pm
